Katharine Batt

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 10

Top Topics

Atrial Fibrillation

Rheumatoid Arthritis Patients

Cerebrospinal Fluid

Top Venues

Expert review of pharmacoeconomics & outcomes research

Haemophilia : the official journal of the World Federation of Hemophilia

Current medical research and opinion

Journal of clinical apheresis

This page only lists publications with an associated author ORCID identifier.

Publications

Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research (2023)
Katharine Batt, Shan Xing, Maja Kuharic, Michael Bullano, Jorge Caicedo, Sreya Chakladar, Riddhi Markan, Sepehr Farahbakhshian
Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs. Haemophilia : the official journal of the World Federation of Hemophilia 29 (3) (2023)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Katharine Batt, Shan Xing, Maja Kuharic, Michael Bullano, Jorge Caicedo, Sreya Chakladar, Riddhi Markan, Sepehr Farahbakhshian
Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs. Haemophilia : the official journal of the World Federation of Hemophilia (2023)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Katharine Batt, Shan Xing, Maja Kuharic, Michael Bullano, Jorge Caicedo, Sreya Chakladar, Riddhi Markan, Sepehr Farahbakhshian
Real-world analysis of patients with haemophilia A and haemophilia A carriers in the United States: Demographics, clinical characteristics and costs. Haemophilia : the official journal of the World Federation of Hemophilia 29 (3) (2023)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research 23 (2) (2023)
Michael Bullano, Christina Cool, Bob G Schultz, Sneha Durgapal, Naomi C Sacks, Yanmei Liu, Rebecca Kee, Katharine Batt
Evaluating the financial impact of utilizing recombinant porcine factor VIII or recombinant FVIIa for patients with acquired hemophilia A. Expert review of pharmacoeconomics & outcomes research (2022)
Katharine Batt, Bob G Schultz, Jorge Caicedo, Christopher S Hollenbeak, Neha Agrawal, Sagnik Chatterjee, Michael Bullano
A real-world study comparing pre-post billed annualized bleed rates and total cost of care among non-inhibitor patients with hemophilia A switching from FVIII prophylaxis to emicizumab. Current medical research and opinion 38 (10) (2022)
Patrick Kuhlman, Peter Miller, Andrew Farland, John Owen, Katharine Batt
Correlating S100B with disease course in a case of new onset, acquired thrombotic thrombocytopenic purpura (TTP): Could this be a new predictive biomarker in TTP? Journal of clinical apheresis 33 (4) (2018)